Interestingly, it has been shown that patients with T2D and obesity treated with GLP-1 agonists (semaglutide or tirzepatide) had significantly lower risks of dementia, stroke, and all-cause mortality compared with those receiving other antidiabetic drugs, but no difference in the risk of Parkinson’s disease or intracerebral hemorrhage [88]. Here, GLP1R is linked to type 2 diabetes mellitus.